Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACIU 
AC Immune Ltd (ACIU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACIU (1-star) is a SELL. SELL since 4 days. Profits (-1.43%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.72
1 Year Target Price $9.72
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.82% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 206.23M USD | Price to earnings Ratio - | 1Y Target Price 9.72 |
Price to earnings Ratio - | 1Y Target Price 9.72 | ||
Volume (30-day avg) 4 | Beta 1.65 | 52 Weeks Range 1.43 - 3.98 | Updated Date 08/29/2025 |
52 Weeks Range 1.43 - 3.98 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.62 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.1742 | Actual -0.21 |
Profitability
Profit Margin -174.67% | Operating Margin (TTM) -1484.53% |
Management Effectiveness
Return on Assets (TTM) -14.64% | Return on Equity (TTM) -50.98% |
Valuation
Trailing PE - | Forward PE 11.24 | Enterprise Value 53773870 | Price to Sales(TTM) 7.13 |
Enterprise Value 53773870 | Price to Sales(TTM) 7.13 | ||
Enterprise Value to Revenue 1.49 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 100600000 | Shares Floating 39960717 |
Shares Outstanding 100600000 | Shares Floating 39960717 | ||
Percent Insiders 38.01 | Percent Institutions 24.72 |
Upturn AI SWOT
AC Immune Ltd
Company Overview
History and Background
AC Immune SA, founded in 2003 in Lausanne, Switzerland, is a clinical-stage biopharmaceutical company specializing in developing therapeutics and diagnostics for neurodegenerative diseases. It has focused on misfolded proteins, particularly amyloid beta, tau, and alpha-synuclein.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Develops antibodies and small molecules targeting misfolded proteins involved in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
- Diagnostics: Creates diagnostic tools for early detection and monitoring of neurodegenerative diseases.
- Partnered Programs: Collaborates with pharmaceutical companies to advance therapeutic candidates through clinical development and commercialization.
Leadership and Structure
Dr. Andrea Pfeifer is the CEO. The company operates with a management team overseeing research, development, clinical operations, and finance. A board of directors provides governance and strategic oversight.
Top Products and Market Share
Key Offerings
- Crenezumab: A humanized anti-Abeta antibody being developed in partnership with Roche/Genentech for Alzheimer's disease. Market share is dependent on successful trial outcomes and regulatory approval. Competitors include Biogen's Aduhelm and Leqembi (lecanemab) from Eisai.
- ACI-35.030 (anti-phospho-tau vaccine): An active immunotherapy (vaccine) candidate designed to induce an antibody response against phosphorylated tau, a key pathological hallmark in Alzheimer's disease and other tauopathies. Competitors are passive anti-tau antibodies being developed by other companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is highly competitive, with significant unmet medical needs. It is characterized by high research and development costs, regulatory hurdles, and clinical trial risks. Success is predicated on innovative approaches to disease modification.
Positioning
AC Immune is positioned as a pioneer in targeting misfolded proteins for neurodegenerative diseases. Its competitive advantage lies in its proprietary technology platforms and collaborations with leading pharmaceutical companies.
Total Addressable Market (TAM)
The Alzheimer's disease market is estimated at tens of billions of dollars annually. AC Immune is positioned to capture a significant share of this TAM if its therapies are successful.
Upturn SWOT Analysis
Strengths
- Proprietary technology platforms targeting misfolded proteins
- Strategic partnerships with major pharmaceutical companies (Roche/Genentech, Janssen)
- Diversified pipeline of therapeutic and diagnostic candidates
- Strong scientific expertise in neurodegenerative diseases
Weaknesses
- High clinical trial risk associated with neurodegenerative disease drug development
- Dependence on partnerships for late-stage development and commercialization
- Limited financial resources compared to larger pharmaceutical companies
- Susceptibility to setbacks from failed clinical trials
Opportunities
- Growing prevalence of neurodegenerative diseases due to aging populations
- Increasing demand for disease-modifying therapies
- Advancements in diagnostic technologies for early disease detection
- Potential for breakthrough therapies targeting underlying disease mechanisms
Threats
- Clinical trial failures leading to pipeline setbacks
- Regulatory hurdles and delays in drug approval
- Competition from established pharmaceutical companies with greater resources
- Patent expirations and generic competition
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- EISIY
Competitive Landscape
AC Immune competes with major pharmaceutical companies developing Alzheimer's disease therapies. Advantages include its innovative technology platforms and partnerships. Disadvantages include its smaller size and limited financial resources compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth has been characterized by periods of significant stock appreciation and downturns, largely tied to progress in clinical trials and partnerships.
Future Projections: Future growth is contingent on the success of its pipeline candidates. Analyst estimates vary considerably based on clinical trial outcomes and regulatory approval prospects.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead candidates and expanding partnerships with pharmaceutical companies.
Summary
AC Immune is a clinical-stage biopharmaceutical company with a focus on neurodegenerative diseases. Its innovative technology platforms and partnerships are strengths, but clinical trial risks and financial constraints are challenges. The company's success hinges on progressing its pipeline and securing regulatory approvals. It faces strong competition from larger pharmaceutical companies and high R&D costs. Overall the company has great potential, but remains speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AC Immune Ltd. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market share data is approximate and based on available estimates. Future performance is subject to numerous risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AC Immune Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-09-23 | Co-Founder, CEO & Director Dr. Andrea Pfeifer Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 133 | Website https://www.acimmune.com |
Full time employees 133 | Website https://www.acimmune.com | ||
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.